---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014642"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:28:41.466297+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coherus Q3 revenue $70.8M, UDENYCA up 30% QoQ; net loss narrows to $10.8M from $39.6M YoY

## Summary
- Net revenue $70.8M; UDENYCA $66.1M (+30% QoQ, +100% YoY); LOQTORZI $5.8M (+54% QoQ).
- Net loss $10.8M ($0.09 loss per share) vs $39.6M loss in Q3 2023; non-GAAP net loss $1.7M.
- UDENYCA supply: CMO resumes production; backlog ~120k units expected by year-end; new CMO testing, commercial supply Q1 2025.
- Pipeline: Phase 2 HCC study of casdozokitug+toripalimab+bevacizumab opening; CHS-114 Phase 1 data expected H1 2025.
- Gross profit improved on divested products (CIMERLI, YUSIMRY); SG&A down $13.5M YoY on lower headcount.

## SEC filing metadata
- accession: 0001558370-24-014642
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024014642/0001558370-24-014642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024014642/chrs-20241106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014642
- JSON: https://secwatch.observer/filing/0001558370-24-014642.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.